Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP067: Risk of malignant and non-malignant complications of the rectal stump in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Bogaerts J.*1, Ten Hove J.R.1, Laclé M.M.2, Meij V.3, Oldenburg B.1

1University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands 2University Medical Center Utrecht, Department of Pathology, Utrecht, Netherlands 3University Medical Center Utrecht, Department of Surgery, Utrecht, Netherlands

DOP068: The virtual electronic chromoendoscopy score in ulcerative colitis exhibits very good inter-rater agreement in scoring mucosal and vascular changes after computerised module training: a study across academic and community practiceECCO '17 Barcelona
Year: 2017
Authors:

Trivedi P.*1,2,3,4, Hodson J.3, Bhala N.4, Cooney R.4, Boulton R.4, Gui X.5, Iqbal T.4, Li K.-k.6, Mumtaz S.7, Pathmakanthan S.4, Quraishi M.N.4, Sagar V.M.1, Shah A.7, Sharma N.8, Siau K.7, Smith S.4, Ward S.9, Widlak M.M.10,11, Ghosh S.3,4, Iacucci M.3,4

1University of Birmingham, NIHR Birmingham Liver Biomedical Research Unit, Birmingham, United Kingdom 2Queen Elizabeth Hospital, Liver Unit, Birmingham, United Kingdom 3University of Birmingham, Institute of Translational Medicine, Birmingham, United Kingdom 4Queen Elizabeth Hospital, Department of Gastroenterology, Birmingham, United Kingdom 5University of Calgary and Calgary Laboratory Services, Department of Pathology and Laboratory Medicine, Calgary, Canada 6Leicester Royal Infirmary, Department of Gastroenterology and Hepatology, Leicester, United Kingdom 7New Cross Hospital, Department of Gastroenterology, Wolverhampton, United Kingdom 8University Hospitals Birmingham Heart of England Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom 9University Hospitals Coventry and Warwickshire, Department of Colorectal Surgery, Coventry, United Kingdom 10University Hospitals Coventry and Warwickshire, Department of Gastroenterology, Coventry, United Kingdom 11University of Warwick, Warwick Medical School, Coventry, United Kingdom

DOP069: Natural history of dysplasia and colorectal cancer in IBD patients in Belgium tertiary care centersECCO '17 Barcelona
Year: 2017
Authors:

Cremer A.*1, Liefferinckx C.1, De Vos M.2, Rahier J.-F.3, Baert F.4, Moreels T.5, Macken E.5, Louis E.6, Devière J.1, Van Gossum A.1, Vermeire S.7, Franchimont D.1

1University Hospital Erasme, Gastroenterology, Brussels, Belgium 2University Hospital Gent, Gastroenterology, Brussels, Belgium 3University Hospital Mont-Godinne, Gastroenterology, Yvoir, Belgium 4AZ Delta, Roeselare, Belgium 5University Hospital Antwerp, Edegem, Belgium 6University Hospital Liège, Liège, Belgium 7University Hospital Leuven, Gastroenterology, Leuven, Belgium

DOP070: Endoscopic response to induction therapy with TNF inhibitors is the best predictor of long term mucosal healing in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Alfaro I.*1, Masamunt M.1, Planell N.2, Lόpez-García A.1, Castro J.1, Gallego M.1, Barastegui R.1, Giner A.1, Vara A.1, Salas A.2, Ricart E.1, Panés J.1, Ordás I.1

1Hospital Clínic, Gastrointestinal Disease, Barcelona, Spain 2Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

DOP071: Comparison of endoscopic responses to adalimumab monotherapy and combination therapy with azathioprine in patients with Crohn's disease: a sub-analysis of DIAMOND trialECCO '17 Barcelona
Year: 2017
Authors:

Watanabe K.*1, Matsumoto T.2, Motoya S.3, Hisamatsu T.4, Nakase H.5, Yoshimura N.6, Ishida T.7, Kato S.8, Nakagawa T.9, Nagahori M.10, Esaki M.11, Matsui T.12, Naito Y.13, Kanai T.14, Suzuki Y.15, Nojima M.16, Watanabe M.10, Hibi T.17

1Osaka City General Hospital, Gastroenterology, Osaka, Japan 2Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan 3Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan 4Kyorin University School of Medicine, Department of Internal Medicine, Tokyo, Japan 5School of Medicine, Sapporo Medical University, Department of Gastroenterology and Hepatology, Sapporo, Japan 6Tokyo Yamate Medical Centre, Department of Medicine, Division of Gastroenterology, Tokyo, Japan 7Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan 8Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan 9Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology, Chiba, Japan 10Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan 11Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan 13Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan 14School of Medicine, Keio University, Department of Internal Medicine, Tokyo, Japan 15Toho University Sakura Medical Center, Department of Internal Medicin, Chiba, Japan 16Institute of Medical Science Hospital, University of Tokyo, Centre for Translational Research, Tokyo, Japan 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan

DOP072: Assessment of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD NetworkECCO '17 Barcelona
Year: 2017
Authors:

Carman N.*1, Huynh H.2, Mouzaki M.3, Crowley E.3, Walsh C.M.3, Ricciuto A.3, Walters T.D.3, Church P.C.3

1The Hospital for Sick Children, Toronto, Canada 2University of Alberta, Edmonton, Canada 3The Hospital for Sick Children, University of Toronto, Gastroenterology Department, Toronto, Canada

DOP073: Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe diseaseECCO '17 Barcelona
Year: 2017
Authors:

Atreya R.*1, Kühbacher T.2,3, Waldner M.J.1, Hirschmann S.1, Drvarov O.2, Abu Hashem R.2, Maaser C.4, Kucharzik T.4, Dinter J.5, Schramm C.5, Mertens J.5, Holler B.6, Mössner J.6, Suzuki K.7, Yokoyama J.7, Terai S.7, Yoneyama H.8, Asakura H.7, Hibi T.9, Neurath M.F.1

1Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany 2Asklepios Westklinikum, Department of Internal Medicine/Gastroenterology, Hamburg, Germany 3Christian Albrechts University Kiel, Department of Internal Medicine/Gastroenterology, Kiel, Germany 4Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Lüneburg, Germany 5Uniklinik Köln, Klinik für Gastroenterologie und Hepatologie, Köln, Germany 6Universitätsklinikum Leipzig, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Leipzig, Germany 7Niigata University Medical and Dental Hospital, Niigata, Japan 8Stelic Institute & Co., Tokyo, Japan 9Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan

DOP074: Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patientsECCO '17 Barcelona
Year: 2017
Authors:

Mukherjee A.*1, D'Haens G.R.2, Sandborn W.J.3, Tsuchiwata S.4, Vong C.5, Deng C.6, Xie R.6, Hazra A.1, Martin S.W.5, Friedman G.7, Niezychowski W.7, Su C.7

1Pfizer Inc, Groton, CT, United States 2Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands 3Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States 4Pfizer Japan Inc, Tokyo, Japan 5Pfizer Inc, Cambridge, MA, United States 6Pfizer Inc, Shanghai, China 7Pfizer Inc, Collegeville, PA, United States

DOP075: Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

D'Haens G.1, Schreiber S.2, Petryka R.3, Kuehbacher T.4, Hebuterne X.5, Roblin X.6, Klopocka M.7, Goldis A.8, Wisniewska-Jarosinska M.9, Baranovsky A.10, Sike R.11, Stoyanova K.12, Meuleners L.13, Tasset C.13, Van der Aa A.13, Harrison P.13, Vermeire S.*14

1Academic Medical Center (AMC), Department of Gastroenterology, Amsterdam, Netherlands 2University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany 3Vivamed, Warsaw, Poland 4Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany 5CHU Nice Hopital l'Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France 6North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France 7NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland 8Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania 9Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland 10City Clinical Hospital #31, St. Petersburg, Russian Federation 11Szent Margit Hospital, Budapest, Hungary 12PSI Pharma Support EOOD, Sofia, Bulgaria 13Galapagos NV, Mechelen, Belgium 14University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium

DOP076: A phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinab, an oral JAK inhibitor, in patients with moderately to severely active ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Sands B.*1, Sandborn W.2, Feagan B.G.3, Lichtenstein G.4, Zhang H.5, Szapary P.5, Panes J.6, Vermeire S.7, O'Brien C.5, Dewey J.5, Yang Z.5, Johanns J.5, Strauss R.5, Marano C.5

1Icahn School of Medicine at Mt Sinai, New York, United States 2University of California San Diego, La Jolla, United States 3Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada 4University of Pennsylvania, Philadelphia, United States 5Janssen Research & Development, LLC, Spring House, United States 6Hospital Clinic Barcelona, IDIBAPS, CIVERehd, Barcelona, Spain 7Uz Leuven, Campus Gasthuisberg, Leuven, Belgium

DOP077: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulatorECCO '17 Barcelona
Year: 2017
Authors:

Lee S.D.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Chiorean M.3

1University of Washington Medical Center, Seattle, United States 2Arena Pharmaceuticals, Inc., San Diego, United States 3Virginia Mason, Digestive Disease Institute, Seattle, United States

DOP078: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulatorECCO '17 Barcelona
Year: 2017
Authors:

Kühbacher T.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Peyrin-Biroulet L.3

1Asklepios Westklinikum Hamburg and Christian Albrechts University, Department of Internal Medicine/Gastroenterology, Kiel, Germany 2Arena Pharmaceuticals, Inc., San Diego, United States 3Nancy University Hospital and Lorraine University, Department of Gastroenterology, Nancy, France

DOP079: The role of intestinal transplant in patients with complicated inflammatory bowel disease: the Cambridge experienceECCO '17 Barcelona
Year: 2017
Authors:

Yeap S.P.*1, Sharkey L.M.1, Woodward J.M.1, Massey D.C.1, Middleton S.J.1, Russell N.K.2, Butler A.J.2

1Addenbrooke's Hospital, Gastroenterology, Cambridge, United Kingdom 2Addenbrooke's Hospital, Transplant Surgery, Cambridge, United Kingdom

DOP080: Low viral richness at baseline in ulcerative ulcerative colitis associated with faecal microbiota transplantation successECCO '17 Barcelona
Year: 2017
Authors:

Conceição-Neto N.*1, Deboutte W.1, Dierckx T.1, Machiels K.2, Wang J.1,3, Yinda C.1, Maes P.1, Van Ranst M.1, Joossens M.1,3, Raes J.1,3, Vermeire S.2, Matthijnssens J.1

1KU Leuven, Rega Institute, Department of Microbiology and Immunology, Leuven, Belgium 2KU Leuven, TARGID, Department of Translational Research Centre for GastroIntestinal Disorders (TARGID), Leuven, Belgium 3VIB, Center for the Biology of Disease, Leuven, Belgium

DOP081: Glycosylation of T cells: a novel targeted-specific therapeutic strategy in IBDECCO '17 Barcelona
Year: 2017
Authors:

Dias A.M.*1,2, Correia A.3, Pereira M.1, Almeida C.R.4, Alves I.1, Lima M.5,6, Marcos-Pinto R.2,7,8, Reis C.A.1,2,9, Vilanova M.2,3, Lago P.8, Pinho S.S.1,9

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & i3S – Instituto de Investigação e Inovação em Saúde, Glycobiology in Cancer, Porto, Portugal 2Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal 3Instituto de Investigação e Inovação em Saude (I3S)/Institute for Molecular and Cell Biology (IBMC), Immunobiology Group, Porto, Portugal 4Instituto de Investigação e Inovação em Saude (I3S)/ Institute of Biomedical Engineering (INEB), NEWTherapies Group, University of Porto, Porto, Portugal 5Centro Hospitalar do Porto, Multidisciplinary Unit for Biomedical Research (UMIB), Porto, Portugal 6Centro Hospitalar do Porto, Hematology Department, Porto, Portugal 7Medical Faculty, Centre for Research in HealthTechnologies and Information Systems (CINTESIS), Porto, Portugal 8Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal 9University of Porto, Medical Faculty, Porto, Portugal

DOP082: Enhanced TH17 responses in patients with IL10 receptor deficiency and history of infantile-onset IBDECCO '17 Barcelona
Year: 2017
Authors:

Shouval D.*1, Konnikova L.2, Werner L.1, Nunberg M.1, Weiss B.1, Glover S.3, Snapper S.2

1Safra Children's Hospital, Pediatric Gastroenterology, Tel Hashomer, Israel 2Boston Children's Hospital, Boston, United States 3University of Florida, Gainesville, United States

DOP083: Recombinant subcutaneous human beta-Defensin 2 (hBD2) ameliorates experimental colitis in different in vivo modelsECCO '17 Barcelona
Year: 2017
Authors:

Mailänder-Sánchez D.1, Kjaerulf S.2, Sidelmann Brinch K.2, Andersen B.2, Stange E.F.1, Malek N.1, Nordkild P.3, Wehkamp J.*1

1University Hospital Tuebingen, Internal Medicine I, Tuebingen, Germany 2Novozymes, Bagsvaerd, Denmark 3Defensin Therapeutics, Copenhagen N, Denmark

DOP084: Peripheral T cell repertoire reconstitution in Crohn's disease patients undergoing autologous HSCTECCO '17 Barcelona
Year: 2017
Authors:

Corraliza A.M.*1, Masamunt M.C.1, Ricart E.1, Lόpez-García A.1, Le Bourhis L.2, Allez M.2, Panés J.1, Salas A.1

1IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain 2Hôpital Saint-Louis, Inserm U1160, Paris, France

DOP085: Tight NADPH oxidase regulation is a prerequisite for gut healthECCO '17 Barcelona
Year: 2017
Authors:

Aviello G.*1,2, Conroy E.3, Bourke B.1, Knaus U.G.1,3

1National Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland 2University of Aberdeen, The Rowett Institute, Aberdeen, United Kingdom 3University College Dublin, Conway Institute, Dublin, Ireland

DOP086: Macrophages from Crohn's disease patients showed a defect to control adherent-invasive Escherichia coli replication influenced by genetic host factorsECCO '17 Barcelona
Year: 2017
Authors:

Buisson A.*1,2, Vazeille E.1,2, Ouchchane L.3, Goutte M.1,2, Hugot J.-P.4, Dubois A.2, Minet Quinard R.5, Bouvier D.5, Bommelaer G.1,2, Barnich N.2

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France 2UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France 3University Hospital G Montpied, Biostatistics unit, clermont-Ferrand, France 4Assistance Publique Hôpitaux de Paris et Université, Paris Diderot, Paris, UMR843, Inserm, Paris, France 5University Hospital G. Montpied, Biochemistry laboratory, Clermont-Ferrand, France